Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
Daraxonrasib, an oral RAS(ON) inhibitor, doubled overall survival and progression-free survival versus chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma across RAS-mutated and wild-type disease in a phase 3 trial.
Hematology/Oncology June 8th 2026
Breastcancer.org
Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.
Hematology/Oncology May 12th 2026
Cardiology Advisor
Patients with primary tricuspid regurgitation had longer survival than those with secondary or lead-associated TR in a 12,899-patient Mayo Clinic retrospective cohort.
Cardiology May 5th 2026
Medical Professionals Reference (MPR)
Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.
Gastroenterology April 28th 2026
Treatment options for platinum‑resistant ovarian cancer remain limited. New phase 3 survival data suggest that adding a novel agent to standard chemotherapy may meaningfully extend survival for this hard‑to‑treat population.
Medical Oncology April 22nd 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS